GoodRx Holdings, Inc. (GDRX)
NASDAQ: GDRX · Real-Time Price · USD
4.080
-0.110 (-2.63%)
At close: Sep 15, 2025, 4:00 PM EDT
4.100
+0.020 (0.48%)
After-hours: Sep 15, 2025, 7:48 PM EDT
GoodRx Holdings Revenue
GoodRx Holdings had revenue of $203.07M in the quarter ending June 30, 2025, with 1.23% growth. This brings the company's revenue in the last twelve months to $799.87M, up 3.20% year-over-year. In the year 2024, GoodRx Holdings had annual revenue of $792.32M with 5.61% growth.
Revenue (ttm)
$799.87M
Revenue Growth
+3.20%
P/S Ratio
1.92
Revenue / Employee
$1,083,840
Employees
738
Market Cap
1.42B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 792.32M | 42.06M | 5.61% |
| Dec 31, 2023 | 750.27M | -16.29M | -2.12% |
| Dec 31, 2022 | 766.55M | 21.13M | 2.83% |
| Dec 31, 2021 | 745.42M | 194.72M | 35.36% |
| Dec 31, 2020 | 550.70M | 162.48M | 41.85% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
GDRX News
- 13 days ago - GoodRx Saddles Up With “The Savings Wrangler,” a Bold New Brand Campaign to Tame the Wild West of Prescription Pricing - Business Wire
- 4 weeks ago - Is Novo Nordisk deal the much-needed catalyst for Goodrx stock? - Invezz
- 4 weeks ago - GoodRx: After A 30% Surge On The Novo News, Is The Story Just Beginning? - Seeking Alpha
- 4 weeks ago - Why is GDRX stock up 30% today? GoodRx strikes deal to sell Ozempic and Wegovy after Novo Nordisk's breakup with Hims - Fast Company
- 4 weeks ago - GoodRx Stock Spikes 35% on Novo Nordisk Collaboration. They're Offering Ozempic for $499 a Month. - Barrons
- 4 weeks ago - GoodRx Announces Collaboration with Novo Nordisk to Expand Access to Ozempic® and Wegovy® for $499-Per-Month - Business Wire
- 5 weeks ago - GoodRx Holdings, Inc. (GDRX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - GoodRx Reports Second Quarter 2025 Results - Business Wire